On September 5, 2019 Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that engineers next-generation human enzymes to provide solutions for diseases with unmet medical need, reported it will present a corporate overview at the 21st Annual H.C. Wainwright Global Investment Conference to be held September 8-10 in New York, NY (Press release, Aeglea BioTherapeutics, SEP 5, 2019, View Source [SID1234539313]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presentation Details
Date: Monday, September 9, 2019
Time: 5:30 p.m. ET
Presenter: Anthony G. Quinn, M.B. Ch.B., Ph.D., Aeglea’s president and chief executive officer
Location: Lotte New York Palace Hotel, New York
Webcast: http://ir.aegleabio.com/events/event-details/hc-wainwright-co-21st-annual-global-investment-conference
To access the live and archived audio webcast, visit the Presentations & Events section of the Aeglea BioTherapeutics investor relations website. Please connect to the website at least 15 minutes prior to the presentation to allow for any software download that may be necessary. Replays of the webcast will be available for 30 days thereafter.